durvalumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancers
Conditions
Biliary Tract Cancers
Trial Timeline
Jul 21, 2023 → Feb 7, 2025
NCT ID
NCT05924880About durvalumab
durvalumab is a phase 3 stage product being developed by AstraZeneca for Biliary Tract Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT05924880. Target conditions include Biliary Tract Cancers.
What happened to similar drugs?
2 of 20 similar drugs in Biliary Tract Cancers were approved
Approved (2) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06992609 | Phase 3 | Recruiting |
| NCT06826677 | Pre-clinical | Completed |
| NCT05925530 | Phase 2 | Active |
| NCT04944173 | Phase 2 | Withdrawn |
| NCT05924880 | Phase 3 | Completed |
| NCT05617963 | Phase 2 | Recruiting |
| NCT05683977 | Pre-clinical | Active |
| NCT05303532 | Phase 3 | Recruiting |
| NCT05215106 | Phase 2 | Recruiting |
| NCT04416633 | Approved | Completed |
| NCT05933044 | Pre-clinical | Completed |
| NCT04765709 | Phase 2 | Terminated |
| NCT04667312 | Pre-clinical | Completed |
| NCT04062708 | Phase 2 | Active |
| NCT04230408 | Phase 2 | Completed |
| NCT04441138 | Phase 2 | Terminated |
| NCT05267392 | Phase 1/2 | UNKNOWN |
| NCT04543110 | Phase 2 | UNKNOWN |
| NCT04716946 | Phase 2 | Active |
| NCT04642469 | Phase 3 | Completed |
Competing Products
20 competing products in Biliary Tract Cancers